Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24 US FDA approval for API manufacturing plant in Mangalore received Acquisition of land in Hyderabad to support long term growth in research services Syngene International Limited
National: After the phenomenal success of the first edition, a revised edition of the book ‘The Perfect Pill: 10 Steps to Build a Strong Healthcare Brand’ by Gauri Chaudhari was launched worldwide recently. The book elaborates on brand-building concepts and suggests necessary steps before applying
Tata Consultancy Services to Help GE HealthCare Advance the Transformation of its Global Information Technology Operating Model to Accelerate Innovation and Improve Resilience Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has expanded its long-standing relationship with GE HealthCare Technologies Inc. (GE HealthCare), a leading
Alkem Laboratories, a renowned pharmaceutical company, announced its entry into the field of Ophthalmology with the launch of an extensive portfolio of affordable and quality eye care products. This strategic expansion demonstrates Alkem's commitment to innovation and its dedication to meeting the diverse needs of
Sanofi Healthcare India Pvt. Ltd. today announced that it has received marketing authorization for Dupixent® (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not
The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
Patients and clinicians are united in a vision for the future; low trust in AI, interoperability, burnout, and care accessibility top the list of challenges Double-blinded quantitative survey of 5,500 patients and patient advocates along with 2,000 clinicians across eight countries, as well as
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
PharmaSynth Formulations Limited, a progressive pharmaceutical company celebrated its 40th Foundation Day across India. The aim of the company is to make available high-quality medicines at affordable prices to the general public with great service. PharmaSynth Company has been honored with many national and international awards.
Records revenue growth of 22% to INR 762 crores in Q4 FY23 & grew 30% to INR 3149 crores in FY23 & operating EBITDA increased by 21% to INR 181 crores in Q4 FY23 A year of market-beating growth, superior performance & an optimistic outlook towards
